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Abstract
This case report describes an 8 year old boy with IVIG resistant Kawasaki disease complicated by
severe bilateral coronary artery aneurysms successfully treated with infliximab, a monoclonal
antibody against tumour necrosis factor alpha.
Background
Kawasaki disease (KD) is associated with the development
of systemic vasculitis complicated by coronary and
peripheral arterial aneurysms, and myocardial infarction
in some patients [1]. KD has an incidence of 8/100 000
children in the UK, and has superseded rheumatic fever in
that KD is now the commonest cause of acquired heart
disease in children in the United Kingdom and the USA
[2]. Treatment with intravenous immunoglobulin (IVIG)
and aspirin reduces the incidence of coronary artery
lesions (CAL) from approximately 20–40% to <5% [1,2],
although recently in the UK we and others have reported
an alarmingly higher incidence of CAL despite IVIG ther-
apy, probably relating to delayed diagnosis of KD in the
UK [3,4]. It is generally accepted that an as yet undefined
infectious trigger in a genetically predisposed individual
results in the disease [5].
Despite intensive research into the illness the cause
remains unknown, and although there have been signifi-
cant improvements in diagnosis and treatment of children
with the disease there are still a number of important
unanswered questions regarding aetiopathogenesis [6],
treatment of IVIG resistant cases, and long-term outlook
[2]. This case report describes an 8 year old male with
severe coronary artery aneurysms (CAA) and ongoing
inflammation despite therapy with IVIG, aspirin and cor-
ticosteroids, treated successfully with infliximab.
Case presentation
The patient was an eight year old boy presenting to his
local hospital with a three day history of pyrexia, irritabil-
ity, erythematous rash in the groin, bilateral knee arthritis
and generalised arthralgia, and a one day history of bilat-
eral non-purulent conjunctivitis. There was no prior past
medical or family history of note and he was fully immu-
nised. Examination revealed red, cracked lips but there
was no lymphadenopathy or clinically overt focus of
infection. Laboratory investigations at that stage revealed
haemoglobin (Hb) 12.6 g/dL (normal reference range
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11.5–15.5 g/dL), white cell count (WCC) 10.6 × 109/L
(4.5–13.5 × 109/L), platelets 444 × 109/L (150–450 × 109/
L), erythrocyte sedimentation rate (ESR) 80 mm/hr (0–10
mm/hr), C-reactive protein (CRP) 143 mg/L (<20 mg/L)
and Albumin (Alb) 32 g/L. He was initially treated symp-
tomatically with paracetamol, ibuprofen and broad spec-
trum antimicrobials, but with no response. All blood
cultures and serology for infections were subsequently
negative. By day 7 of illness he had persistent spiking fever
up to 40.2°C, and developed desquamation of his palms
and soles, and severe colicky central abdominal pain with-
out peritonitis. He had also developed worsening arthritis
in his ankles, wrists and elbows. Repeat laboratory tests
revealed ongoing severe systemic acute phase responses
with ESR 99 mm/hr, CRP 185 mg/L, platelets to 512 ×
109/L and total WCC 11.5 × 109/L. Ultrasound of abdo-
men and hips and bone scan revealed no abnormalities.
Rheumatoid factor, anti-nuclear antibody, autoantibodies
to extractable nuclear antigens, and anti-neutrophil cyto-
plasmic antibodies all proved negative. Renal and liver
function tests were normal and a bone marrow aspirate
demonstrated reactive inflammatory changes with no evi-
dence of malignancy. Electrocardiogram (ECG) revealed
an episode of Wenckebach heart block with baseline tach-
ycardia (heart rate 100 beats per minute). Thereafter,
echocardiography revealed both right and left coronary
artery dilation of 5 mm and a diagnosis of complete
Kawasaki disease was confirmed.
On day 14 of illness, the patient was given Intravenous
Immunoglobulin (IVIG) 2 g/kg over 12 hours and high
dose aspirin. Within 48 hours there was persisting fever
and ongoing severe acute phase response (CRP at 206 mg/
L, WCC 15.4 × 109/L and platelets 822 × 109/L).
A second dose of IVIG 2 g/kg was administered 17 days
after disease onset. Despite this the patient remained
febrile with persisting arthritis and irritability. A repeat
echocardiogram on day 18 of illness revealed left coronary
artery (LCA) dilation of 5.3 mm and right coronary artery
(RCA) of 4.3 mm. His Hb dropped to 6.4 g/dL requiring
transfusion. The patient had also developed a systolic
murmur and repeat echocardiography showed further
RCA dilation of 7 mm and LCA dilation of 5 mm.
On day 32 of illness he was transferred to Great Ormond
St Hospital for Children for further management. Repeat
echocardiography confirmed the severe CAA previously
documented and selective visceral arteriography revealed
pathological calibre variation of the inferior mesenteric
artery (Figure 1A) compatible with medium sized
mesenteric artery vasculitis. At this point, he was given
intravenous methylprednisolone 30 mg/kg daily for three
Arteriographic and echocardiography findings Figure 1
Arteriographic and echocardiography findings. (A) Selective visceral arteriogram demonstrating calibre variation and 
fusiform dilatation of the inferior mesenteric artery (arrows). (B) Echocardiogram on day 34 demonstrated multiple large cor-
onary artery aneurysms including a 7 mm aneurysm affecting the proximal right coronary artery (arrowed). (C) Formal coro-
nary digital subtraction arteriography 9 months after disease onset demonstrating minor ectasia of the left main coronary 
artery (LCA) and proximal circumflex (Circ. a, arrowed) and proximal left anterior descending artery (LAD, arrowed). This is 
most noticeable on the LAD just at the origin of the diagonal artery (Diagonal a, arrowed). The right coronary artery was of a 
normal caliber (not shown).Pediatric Rheumatology 2009, 7:3 http://www.ped-rheum.com/content/7/1/3
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consecutive days followed by oral prednisolone 1 mg/kg
(40 mg) per day for one week thereafter weaning by 5 mg
per week. Despite this he had persistent fever, arthritis,
abdominal pain and irritability although the CRP had
fallen to 25 mg/L. A repeat echocardiogram now showed
deterioration in the CAL with overall RCA dilation of 5.4
mm and with a proximal RCA aneurysm of 7 mm (Figure
1B); left main coronary artery dilation of 6.7 mm and left
anterior descending artery dilation of 5.9 mm with a distal
aneurysm at 6 mm. In view of persisting systemic inflam-
mation and deteriorating CAL on illness day 34 he was
given a single dose of infliximab 6 mg/kg after which he
became afebrile with his arthritis and arthralgia subsiding
within 24 hours. Additionally he was commenced on low
molecular weight (LMW) heparin and warfarin aiming to
achieve a target International Normalised Ratio (INR) of
2–3 after which the LMW heparin was discontinued,
although aspirin was continued at 75 mg once daily.
Thereafter the CAL progressively improved and follow-up
echocardiography 5 months after onset of KD revealed
partial resolution of his coronary dilation: RCA 3.4 mm
and LCA 4 mm proximally and 5.7 mm distally. Formal
coronary digital subtraction arteriography 9 months after
disease onset demonstrated minor ectasia of the left main
coronary artery (LCA) and proximal circumflex and prox-
imal left anterior descending artery. This was most notice-
able on the LAD just at the origin of the diagonal artery.
The right coronary artery was of a normal caliber (Figure
1C).
Discussion
Treatment of KD is aimed at reducing inflammation, pre-
venting the formation of CAA and arterial thrombosis [7].
Up to 15% of patients do not respond to a single dose of
IVIG and a second dose may be required [2,8], although
such IVIG resistant cases may be at higher risk of CAL [2].
Recently it has been suggested that corticosteroids may be
used with comparable efficacy to a second dose of IVIG for
children who fail to respond to the first dose [9].
Our patient was given his first dose of IVIG on illness day
14, but failed to defervesce after two doses of IVIG. In IVIG
resistant KD a number of therapies are reported to be of
benefit such as corticosteroid therapy [10], plasma
exchange, ulinastatin, and therapy directed at blockade of
tumour necrosis factor alpha (TNF-α) [2]. Of these, most
attention has focused on corticosteroids either for IVIG
resistance [9] or as adjunctive first line treatment in com-
bination with IVIG [11,12]. However, evidence based
guidance for alternative treatment if steroids fail (as in our
patient) are lacking. Our patient was treated with a single
dose of infliximab 6 mg/kg. After the infusion his fever
and other systemic symptoms promptly resolved. Encour-
agingly his severe CAAs began to resolve although we can-
not attribute this to infliximab alone. Nonetheless our
case highlights the potential for anti-TNF-α therapy in the
acute management of CAA in the face of ongoing recalci-
trant systemic inflammation.
There are emerging animal data and case reports suggest-
ing efficacy of anti-TNF-α for the treatment of KD [13-21].
The reported clinical cases are summarised in Table 1. Of
note is that the use of infliximab for KD is not widely
reported in the UK or Europe, most cases described from
North America. As yet there have been no published phase
three randomized controlled clinical trials of TNF-α
blockade in KD. In one retrospective study of seventeen
children with IVIG resistant KD infliximab was used suc-
cessfully with abrupt defervescence in 13/16 febrile
patients, with no infusion reactions [18]. Burns et al have
also very recently published a phase 2 clinical trial (Table
1) including 16 subjects receiving infliximab that demon-
strated that this treatment was safe and well tolerated in
patients resistant to IVIG (Table 1) [21]. With IVIG use
now coming under increasing scrutiny in the UK [22] use
of alternative therapies such as TNF-α blockade are likely
to become more widespread, particularly in those with
severe CAL with IVIG resistant inflammation.
Since the recognition that IVIG could reduce the morbid-
ity and mortality of KD, treatment of this condition has
been protocol driven. Although authorities differ in their
advocacy for a variety of treatment protocols, it is likely
that the success of therapeutic intervention in KD is due to
modulation of the causes and/or propagators of inflam-
mation. As such it is perhaps important to re-evaluate the
current prescriptive approach to the management of KD.
Is it correct to persist with interventions in a patient in
whom there is little evidence of clinical and/or laboratory
remission? If ongoing inflammation were damaging to
the vasculature, it would seem logical to assess the success
(or lack of) of any interventions on the basis of cessation
of clinical/laboratory inflammation.
If rapid and effective interruption of inflammation is a pri-
mary target of KD therapy, TNF-α blockade may be useful
as first line therapy, either in place of or adjunctive to IVIG
for the initial treatment of KD. In that context in the UK the
cost of a single dose of 2 g/kg IVIG exceeds that of a single
dose of infliximab, and therefore infliximab could provide
a cheaper alternative to IVIG in the future. As yet, however,
we are unaware of any case reports describing the use of inf-
liximab or other anti-TNF-α therapy as first line therapy for
KD, and this currently remains an experimental albeit
promising novel therapy for IVIG resistant KD.
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